Multiple Sclerosis, Chronic Progressive: all 244 studies

Page 3 of 3. Open to participants first (53), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple SclerosisCompletedNCT02228213Phase 2
• Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple SclerosisStatus unknownNCT02220244Phase 3
• Measuring Active Microglia in Progressive Multiple SclerosisCompletedNCT02207075
• Tear Analysis in the Diagnosis of Multiple SclerosisTerminatedNCT02016222Not applicable
• A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple SclerosisCompletedNCT01917019Phase 3
• Wahls Paleo Diet and Progressive Multiple SclerosisCompletedNCT01915433Not applicable
• MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation TrialCompletedNCT01910259Phase 2
• Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)Status unknownNCT01815632Phase 2
• Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK StudyCompletedNCT01776060
• A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple SclerosisCompletedNCT01737372
• Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple SclerosisCompletedNCT01719159Phase 2
• Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple SclerosisCompletedNCT01684761Phase 2
• Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple SclerosisCompletedNCT01647321Not applicable
• Estriol Treatment in Multiple Sclerosis (MS): Effect on CognitionStatus unknownNCT01466114Phase 2
• Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple SclerosisCompletedNCT01450488Phase 2
• China Betaferon Adherence, Coping and Nurse Support StudyCompletedNCT01436838
• Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple SclerosisCompletedNCT01433497Phase 3
• Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple SclerosisTerminatedNCT01411514Phase 4
• Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)CompletedNCT01381354Phase 1
• Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis OpticaStatus unknownNCT01364246Phase 1/2
• Supported Treadmill Training for Progressive Multiple SclerosisCompletedNCT01339234Not applicable
• Cyclic Oral Methylprednisolone Trial in Multiple SclerosisCompletedNCT01305837Phase 2
• Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectorsCompletedNCT01235455
• AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple SclerosisStatus unknownNCT01228396Phase 2
• Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple SclerosisCompletedNCT01191996Phase 1/2
• Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)WithdrawnNCT01181089Phase 1/2
• The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple SclerosisStatus unknownNCT01144117Phase 2
• Study of Alternative Exercise Therapies for Progressive Multiple Sclerosis (MS)CompletedNCT01097538Not applicable
• Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in ArgentinaCompletedNCT01080014
• Natalizumab Treatment of Progressive Multiple SclerosisCompletedNCT01077466Phase 2
• Bayer/Cognitive Assessments With Multiple Sclerosis SubjectsCompletedNCT00888277
• A Study for Patients With Multiple SclerosisTerminatedNCT00870155Phase 2/3
• A Study for Patients With Secondary Progressive Multiple SclerosisCompletedNCT00869726Phase 2/3
• Autologous Mesenchymal Stem Cell (MSC) Transplantation in MSCompletedNCT00813969Phase 1
• Gene Expression Profiles in Multiple Sclerosis (MS)CompletedNCT00704834
• Dose-Escalation Study of T Cell Vaccine in Multiple SclerosisCompletedNCT00587691Phase 1/2
• Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)CompletedNCT00559702Phase 1
• Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple SclerosisTerminatedNCT00468611Phase 3
• Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple SclerosisStatus unknownNCT00411723Phase 1
• Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)WithdrawnNCT00313976Phase 3
• A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple SclerosisCompletedNCT00257855Phase 2
• Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple SclerosisCompletedNCT00241254Phase 3
• Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) PatientsStatus unknownNCT00220493Phase 1
• Study Evaluating Mitoxantrone in Multiple SclerosisTerminatedNCT00146159Phase 3

← Multiple Sclerosis, Chronic Progressive overview